How addictive drugs disrupt presynaptic dopamine neurotransmission - Test2 - elhamkhani - TriplyDB

How addictive drugs disrupt presynaptic dopamine neurotransmission

How addictive drugs disrupt presynaptic dopamine neurotransmission

http://www.wikidata.org/entity/Q24631269

about

Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity Mechanisms of dopamine transporter regulation in normal and disease states A current view of serotonin transporters Vitamin D receptor and epigenetics in HIV infection and drug abuse Pharmacotherapy for stimulant-related disorders Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter Neurobiology of adolescent substance use and addictive behaviors: treatment implications Illicit dopamine transients: reconciling actions of abused drugs Targeting glutamate uptake to treat alcohol use disorders Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine Common and distinct neural targets of treatment: changing brain function in substance addiction A review of pharmacogenetic studies of substance-related disorders Cocaine-Induced Endocannabinoid Mobilization in the Ventral Tegmental Area Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain.Mechanistic insights into nicotine withdrawal.Brain Histamine N-Methyltransferase As a Possible Target of Treatment for Methamphetamine Overdose Diversity of Dopaminergic Neural Circuits in Response to Drug Exposure How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum Individual differences in the behavioral effects of nicotine: A review of the preclinical animal literature Molecular and functional imaging of internet addiction The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans Dopaminergic neurons inhibit striatal output through non-canonical release of GABA Vesicular integrity in Parkinson's disease Mechanisms of psychostimulant-induced structural plasticity Segregation and crosstalk of D1 receptor-mediated activation of ERK in striatal medium spiny neurons upon acute administration of psychostimulants Chronic ketamine administration modulates midbrain dopamine system in mice Amphetamine elicits opposing actions on readily releasable and reserve pools for dopamine Greater ethanol-induced locomotor activation in DBA/2J versus C57BL/6J mice is not predicted by presynaptic striatal dopamine dynamics Dopamine receptor activation increases HIV entry into primary human macrophages Role for Rab10 in Methamphetamine-Induced Behavior Pharmacosynthetics: Reimagining the pharmacogenetic approach Glycogen synthase kinase-3β inhibition in the medial prefrontal cortex mediates paradoxical amphetamine action in a mouse model of ADHD.KCNQ channels show conserved ethanol block and function in ethanol behaviour.Discovering a new anatomical structure in the brain: implications for neuropsychiatry and therapy.Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.Targeted expression of μ-opioid receptors in a subset of striatal direct-pathway neurons restores opiate reward.The role of the neuropeptide somatostatin on methamphetamine and glutamate-induced neurotoxicity in the striatum of mice Time-dependent changes in nicotine behavioral responsivity during early withdrawal from chronic cocaine administration and attenuation of cocaine sensitization by mecamylamine.

P2860

Q21131062-EE38F6A7-D8A8-4FA1-AC7B-99B29D050CEE Q22251215-39EB0648-1EEA-44FB-AB8D-322324D15283 Q24323196-C6137F11-9AB7-45C0-BA90-07346AA410D6 Q24598750-1B4D1C0C-C3C6-48A2-B08F-16A1E4E36ACC Q26740309-E2D58AC8-FD1F-468B-A25E-8E8021EA84B0 Q26782833-AADE3C0D-9CF7-466E-9A85-7B9541CEAC5D Q26829186-A67339F4-AC23-4643-B004-26A22A47C151 Q26829749-CC7D3315-EC03-4763-986F-DC1C1AF74E6D Q26852735-A34CED41-9F8C-4956-9764-C0ECB67DC6E3 Q26997102-DF1F8071-290A-464F-84CA-D368954EC3D0 Q27002488-45267E47-E834-4A2C-A9BC-9868687CF1EA Q27009552-CFD14B51-FBA7-410B-B1E8-043B7C42C9A9 Q27027961-D07497D5-3202-4CC8-A277-41D889DBE69C Q27312296-6F24FA55-E029-4D7F-AB1A-2EDD0EF2B01C Q27320220-77D9EF3B-1A8E-415C-A28B-5D2B1E32922A Q27333086-2687F7BF-6067-4B34-9BE7-7C5F9A01BFC6 Q27687645-BE9915D0-8B78-453B-93AE-6A67CC911CA7 Q28067373-C38830C7-18B1-4BDC-9843-C82ADF641CCA Q28067590-08147B91-14EB-4032-B87B-3323303465BB Q28078491-370BBFAB-B70D-4090-B92D-603D35803D05 Q28087262-A91FE78C-F53A-4C9F-B806-4699355D566E Q28087601-50BEEA56-E9F3-4A30-9138-8FC576EEC0D8 Q28236333-2062C05F-12C0-47D5-963A-A4A70F71081D Q28276335-44447055-5EBF-47E1-BB66-CAC30C7FD45A Q28385737-1854D346-1981-4451-A4BA-5F8D1C32BCFF Q28389962-520CBA8A-5ACD-437A-87E8-61AC0E19EF4A Q28395155-3EC4E8A7-7FD2-4F21-84EF-988E64E15626 Q28482530-A0D9BCC0-6159-4518-9D04-3B71FE110647 Q28487647-06266911-3C34-4BB2-A79C-6DCABF5D4CC1 Q28537646-8366AC7D-D012-455F-9AB6-75C6940A3FA2 Q28543414-63EBDF9E-1879-461D-ADA0-21123F0F63FD Q28547376-46911B0B-263C-420B-8316-E0F5C3991F3D Q28709274-D8E842C5-C790-4028-B0D0-FE682BCB1201 Q30414710-75CFFC99-1893-4D19-9149-AF4A1F324B15 Q30460166-36077694-C010-45FA-9195-1105E3597C23 Q30485144-71C3C9FB-E2BE-416A-BBE6-FAC6F676A713 Q30581669-7437FCD7-91EC-4663-B752-834C2990B28F Q33559498-238FB5EF-096E-47BA-8FC5-53BCCCDB1C15 Q33575312-A80B737F-DB2B-4F98-82BB-8C9E5411752E Q33625533-0958503A-8219-47DA-91EF-087C33B22453

P2860

How addictive drugs disrupt presynaptic dopamine neurotransmission

http://www.wikidata.org/entity/Q24631269

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

How addictive drugs disrupt presynaptic dopamine neurotransmission

@ast

How addictive drugs disrupt presynaptic dopamine neurotransmission

@en

How addictive drugs disrupt presynaptic dopamine neurotransmission

@nl

type

label

How addictive drugs disrupt presynaptic dopamine neurotransmission

@ast

How addictive drugs disrupt presynaptic dopamine neurotransmission

@en

How addictive drugs disrupt presynaptic dopamine neurotransmission

@nl

prefLabel

How addictive drugs disrupt presynaptic dopamine neurotransmission

@ast

How addictive drugs disrupt presynaptic dopamine neurotransmission

@en

How addictive drugs disrupt presynaptic dopamine neurotransmission

@nl

P1433

Q24631269-3C454015-70ED-4C82-85A6-69DB63A4CB48

P1476

Q24631269-13129A0C-9951-472E-B0AF-6FE893269F18

P2860

Q24631269-020892AD-E946-47B8-8552-42474AFFD1F5

Q24631269-0215E500-AB89-4191-9897-3EA9E79BD482

Q24631269-02E0727A-BFE5-4929-AFCD-3A5699C09FD1

Q24631269-02EEBF62-2979-4F0E-8F73-6B7CE05B936B

Q24631269-053BF7A8-B4F4-4486-AC34-2B8FD7E29CCE

Q24631269-093A9CD2-4B40-4460-823B-05C8666406F9

Q24631269-0E7673D6-2A2E-4208-85BE-1BC0F94DC321

Q24631269-105ECCC0-4139-4B9A-936C-299E12AA6027

Q24631269-10F8CE34-1567-4D34-89B1-C1B413BCADDA

Q24631269-1241861E-5720-4916-9A8B-1D659D5C0F76

P304

Q24631269-27E11FE6-A63B-46BD-8C15-A49B0FA02D11

P31

Q24631269-5A52BC4D-5080-417F-A6D7-DA5702D9019B

P3181

Q24631269-71167C02-1365-40E9-ABB8-506B2806F8BD

P356

Q24631269-CD66EDDF-AF13-48CB-8673-544A45C59828

P407

Q24631269-D06F067F-F331-4855-90FD-4D8F93786288

P433

Q24631269-0AC3727B-7270-4CA1-B577-6A605844F442

P478

Q24631269-BE7CCF51-D27E-4661-9163-1C7E05E0D963

P50

Q24631269-67069A9A-9A93-454C-B057-ADDE54841C54

P577

Q24631269-F646C2CD-CECC-4A38-B2C7-C4DCFA8B5A1C

P5875

Q24631269-62A80C73-F31A-43FB-8A2A-2E820811DABC

P698

Q24631269-8BE7F3E6-816F-4E0D-AD3E-B645E0458040

P921

Q24631269-b2df0a2e-c86b-419c-ac5d-2cf002e20b47

P932

Q24631269-525065B3-0CFA-4D8D-B2BA-5DFCFF2279DC

P3181

P356

J.NEURON.2011.02.010

P1433

P1476

How addictive drugs disrupt presynaptic dopamine neurotransmission

@en

P2860

Acetaldehyde mediates alcohol activation of the mesolimbic dopamine system

Actual Causes of Death in the United States, 2000

Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter

Chemical structure and sympathomimetic action of amines

Temporally resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells

Expression cloning of a reserpine-sensitive vesicular monoamine transporter

Disparity between tonic and phasic ethanol-induced dopamine increases in the nucleus accumbens of rats

P304

628-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4249976

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.NEURON.2011.02.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49852975

http://www.w3.org/2001/XMLSchema#string

P698

21338876

http://www.w3.org/2001/XMLSchema#string

P921

P932

3065181

http://www.w3.org/2001/XMLSchema#string